Evidence map›Paper›PMID 31594780›Full record

ArticleBMJ (Clinical research ed.)2019

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.

Myriam Alexander, A Katrina Loomis, Johan van der Lei, Talita Duarte-Salles, Daniel Prieto-Alhambra, David Ansell, Alessandro Pasqua, Francesco Lapi, Peter Rijnbeek, Mees Mosseveld and 8 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05712603 (A Care Path for the Detection of Advanced NAFLD-fibrosis), which is not on this map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
24.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05712603 completednot on this mapstarted 2022, after this paper: background citation

A Care Path for the Detection of Advanced NAFLD-fibrosis: the Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study - the NLA2 Study

TypeobservationalSponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2022 to 2024Enrolled655ConditionsNon-Alcoholic Fatty Liver DiseaseArmsFIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur".Canadian journal of gastroenterology & hepatology · 2020
    Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 5 countries.

Myriam AlexanderReal World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, Middlesex, UK.
A Katrina LoomisWorldwide Research and Development, Pfizer, Target Sciences, Groton, CT, USA.
Johan van der LeiDepartment of Medical Informatics, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.
Talita Duarte-SallesFundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Daniel Prieto-AlhambraPharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
David AnsellIQVIA, Kings Cross, London, UK.
Alessandro PasquaHealth Search, Italian College of General Practitioners and Primary Care, Firenze, Italy.
Francesco LapiHealth Search, Italian College of General Practitioners and Primary Care, Firenze, Italy.
Peter RijnbeekDepartment of Medical Informatics, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.
Mees MosseveldDepartment of Medical Informatics, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.
Paul AvillachDepartment of Medical Informatics, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.
Peter EggerReal World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, Middlesex, UK.
Nafeesa N DhalwaniDiabetes Research Centre, University of Leicester, Leicester, UK.
Stuart KendrickGlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire, UK.
Carlos Celis-MoralesInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK.
Dawn M WaterworthHuman Genetics, GlaxoSmithKline, Collegeville, PA, USA.
William AlazawiBarts Liver Centre, Blizard Institute, Queen Mary, University of London, London, UK.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0002-1604-2593
Erasmus University Rotterdam · NLGlaxoSmithKline (United Kingdom) · GBSocietà Italiana di Medicina Generale · ITUniversity of Glasgow · GBGlaxoSmithKline (United States) · USHarvard University · USInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESIQVIA (United Kingdom) · GBQueen Mary University of London · GBTarget (United States) · USUniversity of Leicester · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/N00308X/1
6 · The paper itself

Abstract

objectiveTo estimate the risk of acute myocardial infarction (AMI) or stroke in adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

designMatched cohort study.

settingPopulation based, electronic primary healthcare databases before 31 December 2015 from four European countries: Italy (n=1 542 672), Netherlands (n=2 225 925), Spain (n=5 488 397), and UK (n=12 695 046).

participants120 795 adults with a recorded diagnosis of NAFLD or NASH and no other liver diseases, matched at time of NAFLD diagnosis (index date) by age, sex, practice site, and visit, recorded at six months before or after the date of diagnosis, with up to 100 patients without NAFLD or NASH in the same database.

main outcome measuresPrimary outcome was incident fatal or non-fatal AMI and ischaemic or unspecified stroke. Hazard ratios were estimated using Cox models and pooled across databases by random effect meta-analyses.

results120 795 patients with recorded NAFLD or NASH diagnoses were identified with mean follow-up 2.1-5.5 years. After adjustment for age and smoking the pooled hazard ratio for AMI was 1.17 (95% confidence interval 1.05 to 1.30; 1035 events in participants with NAFLD or NASH, 67 823 in matched controls). In a group with more complete data on risk factors (86 098 NAFLD and 4 664 988 matched controls), the hazard ratio for AMI after adjustment for systolic blood pressure, type 2 diabetes, total cholesterol level, statin use, and hypertension was 1.01 (0.91 to 1.12; 747 events in participants with NAFLD or NASH, 37 462 in matched controls). After adjustment for age and smoking status the pooled hazard ratio for stroke was 1.18 (1.11 to 1.24; 2187 events in participants with NAFLD or NASH, 134 001 in matched controls). In the group with more complete data on risk factors, the hazard ratio for stroke was 1.04 (0.99 to 1.09; 1666 events in participants with NAFLD, 83 882 in matched controls) after further adjustment for type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension.

conclusionsThe diagnosis of NAFLD in current routine care of 17.7 million patient appears not to be associated with AMI or stroke risk after adjustment for established cardiovascular risk factors. Cardiovascular risk assessment in adults with a diagnosis of NAFLD is important but should be done in the same way as for the general population.

Indexed as

AdultAgedCohort StudiesDatabases, FactualFemaleFollow-Up StudiesHumansHypertensionIncidenceItalyLiverMaleMiddle AgedMyocardial InfarctionNetherlandsNon-alcoholic Fatty Liver Disease

Identifiers

PMID31594780
PMCPMC6780322
OpenAlexW2979354837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.